Opened in 2004, DNDi‘s office in India supports the implementation of the various R&D projects. The main focus is on visceral leishmaniasis along with activities in hepatitis C, filariasis, and paediatric HIV. The office also works closely on raising awareness and advocating for increased public responsibility and a more enabling environment for neglected disease R&D.


DNDi in India Brochure

Cover page DNDi in India Brochure released in 2019

English
2019

 

 

 



DNDi in India

PHD House, 3rd Floor
4/2 Siri Institutional Area
New Delhi 110016
India

Tel: +91 11 4550 1795

 


  • Supported the Indian National Kala-azar Elimination Programme in building capacity to diagnose kala-azar (visceral leishmaniasis) and post-kala-azar dermal leishmaniasis (PKDL).
  • Completed recruitment for a clinical trial for PKDL, testing amphotericin B monotherapy and an amphotericin B -miltefosine combination, with results expected by mid-2020.
  • Partnered in an MSF study on kala-azar-HIV co-infection in Bihar state to evaluate treatments with amphotericin B monotherapy and an amphotericin B -miltefosine combination, with results expected in 2019 that will provide key evidence to national and regional decision-makers on the best treatment for co-infected patients.
  • Launched the Global Antibiotic Research & Development Partnership (GARDP) 11-country observational study to collect clinical information on treatment of babies with sepsis, to guide the development of new and improved antibiotic treatments for newborns.